Biohaven closes second tranche of $80 mln private placement

Biohaven Pharmaceutical Holding Company Ltd, a clinical stage biopharmaceutical company targeting neurological diseases, including rare disorders, has closed the second tranche of its $80 million private placement. Venrock was the lead investor. Other participants in the financing included Vivo Capital, RA Capital Management, Aisling Capital, Rock Springs Capital, John W. Childs, Greg Bailey, Knoll Capital Management, Osage University Partners, Aperture Venture Partners, Connecticut Innovations and Litmore Capital.

North AmericaUSBriefs